Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta-analysis
- PMID: 34981835
- DOI: 10.1111/all.15205
Comparing biologicals for severe chronic rhinosinusitis with nasal polyps: A network meta-analysis
Comment on
-
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines.Allergy. 2021 Aug;76(8):2337-2353. doi: 10.1111/all.14809. Epub 2021 Mar 24. Allergy. 2021. PMID: 33683704
References
REFERENCES
-
- Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. Allergy. 2021;76:2337-2353.
-
- Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021. doi:10.1016/S2213-2600(21)00097-7
-
- Tversky J, Lane AP, Azar A. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial. Clin Exp Allergy. 2021;51:836-844.
-
- Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2021. doi:10.1016/j.jaci.2021.08.030
-
- Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312-2319. doi:10.1111/all.13875
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
